CD40 Agonism in Cancer Immunotherapy

CD40 is a tumour necrosis factor receptor superfamily member expressed on antigen-presenting cells such as dendritic cells, macrophages and B cells. Engagement by agonistic antibodies or ligands permits these cells to mature, upregulate costimulatory molecules and secrete cytokines, thereby amplifying tumour-specific T cell responses. This strategy can convert immunologically inert “cold” tumours into “hot” lesions characterised by T cell infiltration and pro-inflammatory cytokine profiles. Agonist CD40 immunotherapy has been advanced both as monotherapy and in combination with chemotherapy, radiotherapy or immune checkpoint inhibitors, seeking to optimise delivery methods, dosing regimens and targeting specificity to mitigate systemic toxicity. Recent engineering of antibody frameworks and epitope-directed design have enhanced intrinsic agonistic potency without relying on Fcγ receptor crosslinking, while local intratumoral administration has emerged as a means to reshape the tumour microenvironment and invoke abscopal effects in distant lesions. As several CD40 agonists progress through early-phase clinical evaluation, their global significance lies in broadening the arsenal against malignancies that remain refractory to current immunotherapies.

Research from Nature Portfolio

Advanced antibody engineering has yielded novel conformational formats that intrinsically agonise tumour necrosis factor receptor superfamily members, including CD40. By constraining IgG geometry into an “i-shaped” conformation, these engineered antibodies mimic natural ligand multimerisation to drive potent receptor activation across diverse targets without external crosslinking. Intratumoral delivery of a chimeric membrane-bound CD40 ligand via a nonreplicating adenoviral vector has demonstrated systemic antitumour immunity and eradication of both injected and non-injected melanoma lesions, including those in the brain, when combined with immune checkpoint blockade. This approach elicits a high ratio of cytotoxic CD8+ T cells to regulatory T cells and establishes long-term immune memory.

CD40 Agonism in Cancer Immunotherapy publication trend

The graph below shows the total number of articles in cd40 agonism in cancer immunotherapy across all publications each year (not limited to Nature Index journals).

Technical terms

CD40: A receptor on antigen-presenting cells that enhances immune activation when engaged by its ligand or agonist antibody.

Agonist antibody: An antibody engineered to mimic natural ligand binding, triggering receptor activation rather than blocking it.

Epitope: The specific region on an antigen or receptor to which an antibody binds.

Tumour microenvironment (TME): The local cellular and molecular milieu surrounding a tumour, including immune cells, stroma and cytokines.

Immune checkpoint blockade: Therapeutic inhibition of regulatory pathways (e.g. PD-1, CTLA-4) to enhance T cell-mediated immunity.

Abscopal effect: A systemic antitumour response at sites distant from localised therapy, often immune-mediated.

References

1. i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists. Nature Communications (2024).
2. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nature Communications (2017).
3. Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer. Advanced Science (2023).
4. Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies. Cancer Cell (2018).
5. CCL5 mediates CD40-driven CD4+ T-cell tumor infiltration and immunity. JCI Insight (2020).